logo-loader
ResearchHealth
Redx Pharma Plc

Redx Pharma - Capital Network: Entering the Clinical Stage

Redx Pharma (REDX.LON), a drug discovery and development company focused on oncology, immunology and infectious diseases, is about to move its two lead candidates into the clinical stage.

Executive summary

Redx pharma (REDX.LON) owns RXC005 global IP rights, with key composition-of-matter patents expected to extend up until 2035

Quick facts: Redx Pharma Plc

Price: £0.10

Market: AIM
Market Cap: £12.43 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

'It's a particularly exciting time for Redx Pharma' - Capital Network's...

Capital Network's Healthcare Analyst Riccardo Lowi gives his view on Redx Pharma Plc (LON:REDX). ''The reason it's a particularly exciting time for the company is because they're moving  their two lead candidates into the clinical stage, it's the first time they're moving a drug...

on 04/03/2017

6 min read